Our history

The SYNERLAB Group:

Source of synergies

Immeuble Le Catamaran Entzheim

Our history:

A European group

The SYNERLAB Group is a major player in the pharmaceutical manufacturing sector, which is recognised as one of the European leaders in the markets for:

  • dry forms (tablets, hard and soft capsules, pouches, stick pouches),
  • liquid forms (syrups, oral and nasal drops, stick pouches), sterile liquids with or without preservatives (nasal sprays, eye drops, ear drops),
  • paste-based forms (ointments, creams) and injectable sterile forms.

Its unique know-how in the production of small and medium-sized ranges and its high-performance industrial equipment have made the Group into a privileged partner for all major generic drug manufacturers.

The Group also has a team dedicated to pharmaceutical development. The Synerlab Group proactively supports its customers in the reformulation and development of new galenic forms. This complementary activity is always in great demand.

The Group has also developed a highly diversified customer portfolio, consisting mainly of generic drug manufacturers. It supports increasing numbers of well-known pharmaceutical laboratories in the development and manufacturing of drugs.

Its growing success has led it to become a Group at the head of 6 sites with over 1,000 employees distributed throughout Europe.

Establishment

The Group was established in 2001 and developed from BTT Laboratories in Alsace through regular acquisitions of independent sites located in Europe. These sites all focus on the same core business: the contract development and production of pharmaceutical products. The Group also has its own portfolios of drugs and food supplements.

Key dates

2015 The SYNERLAB acquires ALCALA FARMA Laboratories and extends its industrial footprint into the international sphere.
2013 Ardian, whilst remaining a shareholder, transfers the majority of its shares to the investment fund 21 Centrale Partners, which invests in the SYNERLAB Group.
2012 Successive double acquisition for the SYNERLAB Group: Takeover of LYOFAL and IDD Tech which becomes SYNERLAB DÉVELOPPEMENT.
2010 The SYNERLAB Group acquires PHARMASTER Laboratories from Ms Martin Spittler and develops the site and its product range.
2007 Axa Private Equity (renamed Ardian) becomes the main shareholder of the SYNERLAB Group.
2004 The SYNERLAB Group acquires SOPHARTEX Laboratories from Bouchara Recordati.
2001 Acquisition of the BTT laboratories by Andlinger and establishment of the SYNERLAB Group.
See more